溃疡性结肠炎市场－全球产业规模、份额、趋势、机会和预测，依药物类型、疾病类型、地区和竞争格局划分。 2021-2031年预测

全球溃疡性结肠炎市场规模将从2025年的80.6亿美元成长到2031年的113.6亿美元，复合年增长率为5.89%。溃疡性结肠炎是一种慢性发炎性肠道疾病，其特征是结肠和直肠持续发炎和黏膜溃疡，因此对包括氨基水杨酸盐、皮质类固醇和先进生物製剂在内的药物疗法有着持续的需求。

主要市场驱动因素

新型生物製剂和小分子疗法的加速审批是市场扩张的主要催化剂，直接满足了对传统疗法无效患者的临床需求。监管机构越来越多地批准具有不同作用机制的药物，例如白细胞介素-23抑制剂和Janus激酶抑制剂，这丰富了胃肠病学家可用的治疗手段。

主要市场挑战

新型生物製剂和小分子疗法的高昂价格严重限制了全球溃疡性结肠炎市场的成长。儘管这些先进疗法能够带来必要的临床缓解，但其高昂的费用迫使公共和私人支付方实施严格的成本控制措施，例如分级纳入药品目录和严格的预先审批要求。

主要市场趋势

经济实惠的生物相似药的涌现，正在从根本上重塑全球溃疡性结肠炎市场，打破现有重磅药物的专利垄断地位。随着乌司奴单抗和阿达木单抗等旗舰疗法的专利保护到期，高品质生物相似药的积极进入市场，加剧了价格竞争，并扩大了此前因价格高昂而难以获得生物製剂治疗的患者群体。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球溃疡性结肠炎市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类型（抗发炎药、抗TNF生物製剂、免疫抑制剂、钙调磷酸酶抑制剂及其他）
  • 依疾病类型（溃疡性直肠炎、直肠乙状结肠炎、左侧结肠炎、全结肠炎或普遍性结肠炎、暴发性结肠炎）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美溃疡性结肠炎市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲溃疡性结肠炎市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区溃疡性结肠炎市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲溃疡性结肠炎市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲溃疡性结肠炎市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球溃疡性结肠炎市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Johnson and Johnson
• Allergan, Inc.
• Merck & Co., Inc.
• Novartis AG
• Bausch Health Companies Inc.
• AstraZeneca Plc
• Eli Lilly & Company
• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline Plc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Ulcerative Colitis Market will grow from USD 8.06 Billion in 2025 to USD 11.36 Billion by 2031 at a 5.89% CAGR. Ulcerative colitis is a chronic inflammatory bowel disease characterized by continuous inflammation and mucosal ulceration in the colon and rectum, creating a sustained demand for pharmacotherapies including aminosalicylates, corticosteroids, and advanced biologics.

Key Market Drivers

The accelerated approval of novel biologics and small molecule therapies serves as a primary catalyst for market expansion, directly addressing the clinical needs of patients refractory to conventional treatments. Regulatory agencies are increasingly authorizing agents with distinct mechanisms of action, such as interleukin-23 inhibitors and Janus kinase inhibitors, which diversifies the therapeutic arsenal available to gastroenterologists. This regulatory momentum ensures a steady influx of advanced treatment options that offer improved remission rates and safety profiles, encouraging healthcare providers to switch patients from older protocols to newer, more effective regimens.

Key Market Challenges

The prohibitive pricing of novel biologic and small molecule therapies constitutes a severe restraint on the growth of the global ulcerative colitis market. Although these advanced treatments provide necessary clinical remission, their substantial costs compel public and private payers to implement stringent cost-containment measures, such as tiered formulary placement and rigorous prior authorization requirements. These financial barriers frequently force physicians to reserve high-efficacy drugs for only the most severe cases, effectively capping the sales volume of premium products and slowing revenue generation across the sector.

Key Market Trends

The proliferation of cost-effective biosimilars for major biologics is fundamentally reshaping the global ulcerative colitis market by dismantling the exclusivity of incumbent blockbusters. As patent protections for flagship therapies like ustekinumab and adalimumab expire, the aggressive entry of high-quality biosimilars is driving price competition and expanding patient access to biologic treatments previously restricted by prohibitive costs.

Key Market Players

• Johnson and Johnson
• Allergan, Inc.
• Merck & Co., Inc.
• Novartis AG
• Bausch Health Companies Inc.
• AstraZeneca Plc
• Eli Lilly & Company
• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline Plc.

Report Scope:

In this report, the Global Ulcerative Colitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ulcerative Colitis Market, By Drug Type:

• Anti-Inflammatory Drugs
• Anti-TNF biologics
• Immuno-suppressants
• Calcineurin Inhibitors
• and Other

Ulcerative Colitis Market, By Disease Type:

• Ulcerative Proctitis
• Proctosigmoiditis
• Left-sided Colitis
• Pancolitis or Universal Colitis
• and Fulminant Colitis

Ulcerative Colitis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ulcerative Colitis Market.

Available Customizations:

Global Ulcerative Colitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ulcerative Colitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Anti-Inflammatory Drugs, Anti-TNF biologics, Immuno-suppressants, Calcineurin Inhibitors, and Other)
  • 5.2.2. By Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Ulcerative Colitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Ulcerative Colitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Disease Type
  • 6.3.2. Canada Ulcerative Colitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Disease Type
  • 6.3.3. Mexico Ulcerative Colitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Disease Type

7. Europe Ulcerative Colitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Ulcerative Colitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Disease Type
  • 7.3.2. France Ulcerative Colitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Disease Type
  • 7.3.3. United Kingdom Ulcerative Colitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Disease Type
  • 7.3.4. Italy Ulcerative Colitis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Disease Type
  • 7.3.5. Spain Ulcerative Colitis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Disease Type

8. Asia Pacific Ulcerative Colitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Ulcerative Colitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Disease Type
  • 8.3.2. India Ulcerative Colitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Disease Type
  • 8.3.3. Japan Ulcerative Colitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Disease Type
  • 8.3.4. South Korea Ulcerative Colitis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Disease Type
  • 8.3.5. Australia Ulcerative Colitis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Disease Type

9. Middle East & Africa Ulcerative Colitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Ulcerative Colitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Disease Type
  • 9.3.2. UAE Ulcerative Colitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Disease Type
  • 9.3.3. South Africa Ulcerative Colitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Disease Type

10. South America Ulcerative Colitis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Ulcerative Colitis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Disease Type
  • 10.3.2. Colombia Ulcerative Colitis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Disease Type
  • 10.3.3. Argentina Ulcerative Colitis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Disease Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Ulcerative Colitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Johnson and Johnson
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Allergan, Inc.
• 15.3. Merck & Co., Inc.
• 15.4. Novartis AG
• 15.5. Bausch Health Companies Inc.
• 15.6. AstraZeneca Plc
• 15.7. Eli Lilly & Company
• 15.8. Pfizer Inc.
• 15.9. Sanofi SA
• 15.10. GlaxoSmithKline Plc.

16. Strategic Recommendations

17. About Us & Disclaimer